Compare Meta Platforms Inc (META) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Meta Platforms Inc vs Repligen Corporation Common Stock — how do they compare? Meta Platforms Inc trades at $725.56 (market cap $1.94T), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Meta Platforms Inc is far larger — about 174.1× Repligen Corporation Common Stock's market cap, and Meta Platforms Inc pays a 0.28% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Meta Platforms Inc for 128 Days and Repligen Corporation Common Stock for 0 Days on average.
| META | RGEN | |
|---|---|---|
Market Cap | $1.94T | $11.14B |
Volume | 22,627,792 | 1,259,263 |
Sector | Media | Health |
52-Week High | $777.59 | $194.57 |
52-Week Low | $525.72 | $102.87 |
Typical Hold Time | 128 Days | 0 Days |
Enterprise Value | $1.96T | $11.02B |
Dividend Yield | 0.28% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Meta Platforms (META) trades at $737.54, down 0.73% on the day, with strong bullish technical signals from moving averages and ADX indicators. The company demonstrates robust fundamentals with $201B revenue in 2025, 29.8% net margin, and consistent earnings beats in recent quarters. Recent AI developments including Muse Spark launch and a $21B CoreWeave deal highlight growth initiatives.
Wall Street maintains strong bullish sentiment with 80% buy ratings and $802.80 consensus target, representing 9% upside. Key risks include ongoing youth addiction litigation in Massachusetts and elevated capital expenditures for AI infrastructure. The stock presents growth potential through AI monetization but faces regulatory and execution challenges.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
